Motif Bio Share Discussion Threads

[lionheart69uk1] 27/11/2019 09:20

Am expecting a massive Santa rally. Watch this space.

[texaschaser] 27/11/2019 08:49

Can this go any lower? Answer not even needed on postcard. Yes it can and will.

[sunningdale1] 26/11/2019 11:36

ORPH Update - Maurice Treacy, CCO of Open Orphan #ORPH reveals they have signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform on the Vox Podcast.

The interview starts at 10 minutes.

hxxps://audioboom.com/posts/7433540-nuformix-open-orphan-zoetic-international-and-live-company-group

[telbap] 21/11/2019 13:34

£340k on today's share price ......reasonable chunk of cash

[telbap] 21/11/2019 13:33

Peel hunt upto 18%

[zen12] 15/11/2019 07:55

Company back from the dead..GM passed by shareholders. There is still life left in this...Iclaprim sale next.

[zen12] 14/11/2019 19:11

It's no suspension - GM all resolution passed!

[sunningdale1] 14/11/2019 19:06

Nice little rise in the share price today. For those that were interested in my previous post on ORPH big news this week as Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

CEO Cathal Friel commented:
“When we completed the reverse takeover of Venn earlier this summer we promised shareholders that one of our key objectives would be to transform Venn into a profitable pharma services company. This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector. I look forward to announcing more positive news in due course.”

CEO Cathal Friel ensures this is not an exclusive offer but Venn have more to come in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

[zen12] 14/11/2019 16:49

GM tonight...result should be interesting.

[small crow] 28/10/2019 10:11

£14,000 smacked down on the table this morning.

[rk23] 24/10/2019 07:36

Motif Bio PLC U.S. Army-funded project to Evaluate IclaprimSource: UK Regulatory (RNS & others)TIDMMTFBRNS Number : 9200QMotif Bio PLC24 October 2019Motif Bio plc("Motif Bio" or the "Company")U.S. Army-funded research project to Evaluate IclaprimMotif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.The aerosol technology allows delivery of antibiotics painlessly and rapidly into skin and soft tissue with low-pressure and focused delivery. The research is being funded through a grant from the U.S. Department of Defense - Congressionally Directed Military Infectious Diseases Research Program to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield. The work will be led by Dr. Daniel Zurawski, Ph.D., Chief, Pathogenesis and Virulence, WRAIR/Wound Infections Dept./Bacterial Diseases Branch.David Huang, M.D., Ph.D., Chief Medical Officer of Motif Bio, said: "When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible. The data generated from Dr. Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections."This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

[zen12] 21/10/2019 10:18

They'll burn the 600k by end of month...so it's sqweeky time!

[w0lf0fwallstreet] 18/10/2019 13:01

Deal about to be announced

[zen12] 11/10/2019 08:28

Bit boring now from MMs, don't we see this every morning here a sell at ridiculous 15-20% discount!

[zen12] 10/10/2019 14:39

No money - is that not why they raised 600k last week lol Now don't tell me that won't last long...it may give them enough time to do a deal, my guess they're already talking to many with Hercules.

[pugugly] 10/10/2019 14:06

Traditional Sale - Not as hope in HELL (imo)
Shareholders will be very lucky if management are able to negotiate a "free assignment" of ALL research data and IP to another pharma in return for an agreement for a fee of �xxx,000 if new phase 3 results pass FDA and a y% royalty on ongoing sales - subject to which pharma the execution of the terms of this agreement might need to be insured by Lloyds or similar reputable insurance organisation against default.

[shirley83] 10/10/2019 13:48

ZEN, sales talks take months. They have no money.

[philoosh] 10/10/2019 13:41

All i know is that my shares are pretty much worthless now so I wont sell for a pittance. My fingers are crossed this comes good but if it doesn't its just beer money i'd lose now!

[vulgaris] 10/10/2019 13:30

HABP/VAP trial costlier & slower to recruit than cABSSSI (skin).

..... &, against what comparator? Still vancomycin? Or vs. linezolid, where there's some (albeit weak) evidence of superiority over vancomycin (unlike in ABSSSI).

Directors keen to keep themselves occupied for a few more years at investors' expense.

[pjj71] 10/10/2019 13:08

the FDA led the board down a garden path for the last 3 years... and they continue to do so.. if there was a glimmer of hope of iclaprim passing they would have given a box warning.. sell to 0

[zen12] 10/10/2019 10:41

..if that was the case FDA wouldn't have been collaborating with MTBF since Feb (8 months), to agree the limited trial and its approval route. It looks like it's been simplified for whoever picks this up. We should now start to see interested parties come forward.

[pjj71] 10/10/2019 10:18

which pharma is going to spend more money after 2 failed phase 3 trials.. the FDA clearly dont want this compound to succeed hence the requirement for yet another trial costing millions and millions to quote the CEO...